Owkin unveils K Pro, first agentic AI co-pilot built for biopharma

Owkin has launched K Pro, its new agentic AI “co-pilot” tailored for the biopharma sector. The tool is designed to support decision-making throughout drug research and development by linking deep biological reasoning with pipeline strategy. K Pro builds on Owkin’s existing platform of multimodal patient data and AI modeling to deliver insight, de-risk key steps, and accelerate alignment across teams.

The platform allows users to explore hypotheses, evaluate biomarkers, and assess competitive landscapes through a natural language interface, translating biological complexity into clear, actionable insights. K Pro’s architecture rests on “agentic spaces” — modular agents that analyze, activate, and amplify insights for trial design and biology translation.

Behind it all is a curated network of multimodal patient datasets (including spatial omics, imaging, genomics) and Owkin’s years of experience integrating and reasoning across complex biological data. The company is rolling out pilot programs with select pharma partners, making K Pro available first in trial mode. 

Owkin contrasts K Pro with more general large language models by emphasizing its grounding in biology rather than abstract, text-based reasoning. The ambition is that, over time, K Pro could evolve from a human-augmented co-pilot into a more autonomous research partner — while preserving transparency, traceability, and scientific rigor. 

This move positions Owkin at the frontline of a new class of AI tools in pharma, where agents are purpose-designed to reason with biology rather than general purpose text tasks. The success of K Pro will depend on its adoption, integration with proprietary data, and ability to maintain reliability and trust in regulated environments.